FRM
INZY

Fox Run Management’s Inozyme Pharma INZY Stock Holding History

Fox Run Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,309
Closed -$80.1K – 1014
2024
Q3 		$80.1K Buy
+15,309
New +$79.5K 0.02% 752

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fox Run Management's INZY Position: Q4 2024 in Review

Fox Run Management sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 15,309 shares — an estimated $80.1K sold.

Fox Run Management first reported a position in INZY in Q3 2024 and held it in 1 quarter. The position peaked at $80.1K in Q3 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • Fox Run Management reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • Fox Run Management sold 15,309 Inozyme Pharma shares in Q4 2024, an estimated $80.1K.
  • Fox Run Management first reported a position in Inozyme Pharma in Q3 2024 and held it in 1 quarter.
  • Fox Run Management's Inozyme Pharma position peaked at $80.1K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on Fox Run Management's 13F filing for Q4 2024, filed 11 Feb 2025.